147 related articles for article (PubMed ID: 30023998)
1. Polysaccharides from Burkholderia species as targets for vaccine development, immunomodulation and chemical synthesis.
Cloutier M; Muru K; Ravicoularamin G; Gauthier C
Nat Prod Rep; 2018 Dec; 35(12):1251-1293. PubMed ID: 30023998
[TBL] [Abstract][Full Text] [Related]
2. Development of capsular polysaccharide-based glycoconjugates for immunization against melioidosis and glanders.
Burtnick MN; Heiss C; Roberts RA; Schweizer HP; Azadi P; Brett PJ
Front Cell Infect Microbiol; 2012; 2():108. PubMed ID: 22912938
[TBL] [Abstract][Full Text] [Related]
3. Burkholderia pseudomallei and Burkholderia mallei vaccines: Are we close to clinical trials?
Titball RW; Burtnick MN; Bancroft GJ; Brett P
Vaccine; 2017 Oct; 35(44):5981-5989. PubMed ID: 28336210
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders.
Moustafa DA; Scarff JM; Garcia PP; Cassidy SK; DiGiandomenico A; Waag DM; Inzana TJ; Goldberg JB
PLoS One; 2015; 10(7):e0132032. PubMed ID: 26148026
[TBL] [Abstract][Full Text] [Related]
5. Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders.
Sarkar-Tyson M; Smither SJ; Harding SV; Atkins TP; Titball RW
Vaccine; 2009 Jul; 27(33):4447-51. PubMed ID: 19490962
[TBL] [Abstract][Full Text] [Related]
6. Burkholderia vaccines: are we moving forward?
Choh LC; Ong GH; Vellasamy KM; Kalaiselvam K; Kang WT; Al-Maleki AR; Mariappan V; Vadivelu J
Front Cell Infect Microbiol; 2013; 3():5. PubMed ID: 23386999
[TBL] [Abstract][Full Text] [Related]
7. Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei.
Bondi SK; Goldberg JB
Expert Rev Vaccines; 2008 Nov; 7(9):1357-65. PubMed ID: 18980539
[TBL] [Abstract][Full Text] [Related]
8. Development of Burkholderia mallei and pseudomallei vaccines.
Silva EB; Dow SW
Front Cell Infect Microbiol; 2013; 3():10. PubMed ID: 23508691
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Burkholderia mallei ΔtonB Δhcp1 (CLH001) as a live attenuated vaccine in murine models of glanders and melioidosis.
Khakhum N; Bharaj P; Myers JN; Tapia D; Walker DH; Endsley JJ; Torres AG
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007578. PubMed ID: 31306423
[TBL] [Abstract][Full Text] [Related]
10. Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches.
Aschenbroich SA; Lafontaine ER; Hogan RJ
Expert Rev Vaccines; 2016 Sep; 15(9):1163-81. PubMed ID: 27010618
[TBL] [Abstract][Full Text] [Related]
11. Development of novel O-polysaccharide based glycoconjugates for immunization against glanders.
Burtnick MN; Heiss C; Schuler AM; Azadi P; Brett PJ
Front Cell Infect Microbiol; 2012; 2():148. PubMed ID: 23205347
[TBL] [Abstract][Full Text] [Related]
12. [Burkholderia mallei and Burkholderia pseudomallei. Study of immuno- and pathogenesis of glanders and melioidosis. Heterologous vaccines].
Manzeniuk IN; Galina EA; Dorokhin VV; Kalachev IIa; Borzenkov VN; Svetoch EA
Antibiot Khimioter; 1999; 44(6):21-6. PubMed ID: 10422574
[TBL] [Abstract][Full Text] [Related]
13. Antibodies against
Zimmerman SM; Dyke JS; Jelesijevic TP; Michel F; Lafontaine ER; Hogan RJ
Infect Immun; 2017 Aug; 85(8):. PubMed ID: 28507073
[No Abstract] [Full Text] [Related]
14. [Immunobiological properties of Burkholderia pseudomallei and Burkholderia mallei capsular substances].
Popov SF; Tikhonov NG; Piven' NN; Avrorova IV; Viktorov DV; Kurilov VIa
Zh Mikrobiol Epidemiol Immunobiol; 2002; (6):60-4. PubMed ID: 12506631
[TBL] [Abstract][Full Text] [Related]
15. Current Advances in
Wang G; Zarodkiewicz P; Valvano MA
Cells; 2020 Dec; 9(12):. PubMed ID: 33322641
[TBL] [Abstract][Full Text] [Related]
16. Structural characterisation of the capsular polysaccharide expressed by Burkholderia thailandensis strain E555:: wbiI (pKnock-KmR) and assessment of the significance of the 2-O-acetyl group in immune protection.
Bayliss M; Donaldson MI; Nepogodiev SA; Pergolizzi G; Scott AE; Harmer NJ; Field RA; Prior JL
Carbohydr Res; 2017 Nov; 452():17-24. PubMed ID: 29024844
[TBL] [Abstract][Full Text] [Related]
17. [Immunogenic potential of glanders and melioidosis agents].
Kalachev II; Baídus' AN; Ivanova OA; Ganina EA; Boldyrev IA; Svetoch EA
Vestn Ross Akad Med Nauk; 1997; (6):32-7. PubMed ID: 9289277
[TBL] [Abstract][Full Text] [Related]
18. Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence determinant.
DeShazer D; Waag DM; Fritz DL; Woods DE
Microb Pathog; 2001 May; 30(5):253-69. PubMed ID: 11373120
[TBL] [Abstract][Full Text] [Related]
19. Exploiting molecular virulence determinants in Burkholderia to develop vaccine antigens.
Casey WT; McClean S
Curr Med Chem; 2015; 22(14):1719-33. PubMed ID: 25850766
[TBL] [Abstract][Full Text] [Related]
20.
Badten AJ; Torres AG
Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543947
[No Abstract] [Full Text] [Related]
[Next] [New Search]
